Literature DB >> 18758939

TAT-mediated protein transduction of Nogo extracellular peptide 1-40 and its biological activity.

Qiang Wang1, Xingchun Gou, Weilin Jin, Lize Xiong, Lichao Hou, Shaoyang Chen, Hui Zhang, Xiaoling Zhu, Lixian Xu.   

Abstract

AIM: Nogo extracellular peptide 1-40 (NEP1-40), a Nogo-66 antagonistic peptide, is one of the potential candidates for therapeutic intervention after central nervous system injury. This study is focused on the generation of TAT-NEP1-40 fusion protein and its transducible effects and biological activity.
METHODS: TAT-NEP1-40 fusion protein was expressed in vitro. Transducible effects of TAT-NEP1-40 were analyzed by using immunofluorescence staining or Western blot in vitro and in vivo. The biological activity of TAT-NEP1-40 was assessed by its effects against oxygen and glucose deprivation (OGD)-induced PC12 cell damages.
RESULTS: Our results showed that the TAT-NEP1-40 fusion protein was successfully expressed, purified, and refolded. Western blot analysis and immunofluorescence staining confirmed the delivery of TAT-NEP1-40 protein into PC12 cells and rat brains. OGD caused cell apoptosis or death, decreased cell viability, increased lactate dehydrogenase release in medium and the Bax/Bcl-2 ratio, all of which were prevented by the TAT-NEP1-40 fusion proteins when added exogenously to culture medium. In addition, TAT-NEP1-40 promoted neurite outgrowth of PC12 cells exposed to OGD.
CONCLUSION: These results demonstrate that the TAT-NEP1-40 can be successfully generated and efficiently transduced into PC12 cells and rat brains. The TAT-NEP1-40 can protect PC12 cells against OGD and promote neurite outgrowth. This finding suggests that the transducible TAT-NEP1-40 fusion protein offers a possibility of the development of novel therapy for cerebral injuries via delivery of the biologically active TAT-NEP1-40 fusion protein into injured sites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758939     DOI: 10.1007/s10571-008-9301-2

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  34 in total

Review 1.  Drug delivery to the central nervous system: a review.

Authors:  Ambikanandan Misra; S Ganesh; Aliasgar Shahiwala; Shrenik P Shah
Journal:  J Pharm Pharm Sci       Date:  2003 May-Aug       Impact factor: 2.327

2.  LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.

Authors:  Sha Mi; Xinhua Lee; Zhaohui Shao; Greg Thill; Benxiu Ji; Jane Relton; Melissa Levesque; Norm Allaire; Steve Perrin; Bryan Sands; Thomas Crowell; Richard L Cate; John M McCoy; R Blake Pepinsky
Journal:  Nat Neurosci       Date:  2004-02-15       Impact factor: 24.884

Review 3.  TAT fusion proteins against ischemic stroke: current status and future perspectives.

Authors:  Ertugrul Kilic; Ulkan Kilic; Dirk M Hermann
Journal:  Front Biosci       Date:  2006-05-01

4.  Delayed treatment with monoclonal antibody IN-1 1 week after stroke results in recovery of function and corticorubral plasticity in adult rats.

Authors:  Andrew B Seymour; Ellen M Andrews; Shih-Yen Tsai; Tiffanie M Markus; Melanie R Bollnow; Miranda M Brenneman; Timothy E O'Brien; Anthony J Castro; Martin E Schwab; Gwendolyn L Kartje
Journal:  J Cereb Blood Flow Metab       Date:  2005-10       Impact factor: 6.200

5.  Role of Bcl-2 family of proteins in mediating apoptotic death of PC12 cells exposed to oxygen and glucose deprivation.

Authors:  David Koubi; Hao Jiang; Lijie Zhang; Wenxue Tang; Jarret Kuo; Alba I Rodriguez; Tangella Jackson Hunter; Michael D Seidman; George B Corcoran; Robert A Levine
Journal:  Neurochem Int       Date:  2005-01       Impact factor: 3.921

6.  The effect of polypyrrole with incorporated neurotrophin-3 on the promotion of neurite outgrowth from auditory neurons.

Authors:  Rachael T Richardson; Brianna Thompson; Simon Moulton; Carrie Newbold; May Ghee Lum; Adrian Cameron; Gordon Wallace; Robert Kapsa; Graeme Clark; Stephen O'Leary
Journal:  Biomaterials       Date:  2006-09-27       Impact factor: 12.479

7.  Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth.

Authors:  Marco Domeniconi; Zixuan Cao; Timothy Spencer; Rajeev Sivasankaran; Kevin Wang; Elena Nikulina; Noriko Kimura; Hong Cai; Kangwen Deng; Ying Gao; Zhigang He; Marie Filbin
Journal:  Neuron       Date:  2002-07-18       Impact factor: 17.173

8.  Transduced Tat-SOD fusion protein protects against ischemic brain injury.

Authors:  Dae Won Kim; Won Sik Eum; Sang Ho Jang; So Young Kim; Hee Soon Choi; Soo Hyun Choi; Jae Jin An; Sun Hwa Lee; Kil Soo Lee; Kyuhyung Han; Tae-Cheon Kang; Moo Ho Won; Jung Hoon Kang; Oh-Shin Kwon; Sung-Woo Cho; Tae Yoon Kim; Jinseu Park; Soo Young Choi
Journal:  Mol Cells       Date:  2005-02-28       Impact factor: 5.034

Review 9.  Protein transduction technology offers novel therapeutic approach for brain ischemia.

Authors:  Catherine Denicourt; Steven F Dowdy
Journal:  Trends Pharmacol Sci       Date:  2003-05       Impact factor: 14.819

Review 10.  Transcellular protein transduction using the Tat protein of HIV-1.

Authors:  Antonio Fittipaldi; Mauro Giacca
Journal:  Adv Drug Deliv Rev       Date:  2005-01-25       Impact factor: 15.470

View more
  6 in total

1.  Nogo-66 inhibits the dye-coupling of astrocytic gap junctions in vitro.

Authors:  Yazhou Wang; Yin Wu; Mengdong Liu; Jian Wang; Gong Ju
Journal:  Neurochem Res       Date:  2011-04-02       Impact factor: 3.996

Review 2.  Peptide Pharmacological Approaches to Treating Traumatic Brain Injury: a Case for Arginine-Rich Peptides.

Authors:  Li Shan Chiu; Ryan S Anderton; Neville W Knuckey; Bruno P Meloni
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

3.  Microglial phenotype is regulated by activity of the transcription factor, NFAT (nuclear factor of activated T cells).

Authors:  Kumi Nagamoto-Combs; Colin K Combs
Journal:  J Neurosci       Date:  2010-07-14       Impact factor: 6.167

4.  Electroacupuncture pretreatment attenuates cerebral ischemic injury through α7 nicotinic acetylcholine receptor-mediated inhibition of high-mobility group box 1 release in rats.

Authors:  Qiang Wang; Feng Wang; Xin Li; Qianzi Yang; Xuying Li; Ning Xu; Yi Huang; Qiaomei Zhang; Xingchun Gou; Shaoyang Chen; Lize Xiong
Journal:  J Neuroinflammation       Date:  2012-01-26       Impact factor: 8.322

5.  Neuroprotective effects of sevoflurane against electromagnetic pulse-induced brain injury through inhibition of neuronal oxidative stress and apoptosis.

Authors:  Bin Deng; Hao Xu; Jin Zhang; Jin Wang; Li-Chun Han; Li-Ya Li; Guang-Li Wu; Yan-Ning Hou; Guo-Zhen Guo; Qiang Wang; Han-Fei Sang; Li-Xian Xu
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

6.  Cationic Arginine-Rich Peptides (CARPs): A Novel Class of Neuroprotective Agents With a Multimodal Mechanism of Action.

Authors:  Bruno P Meloni; Frank L Mastaglia; Neville W Knuckey
Journal:  Front Neurol       Date:  2020-02-25       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.